Expanding the Presbyopia Practice: Growing the Population of Happy Presbyopia Patients With the Latest Technologies

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, NY

Marjan Farid, MD

Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, California

Karolinne M. Rocha, MD, PhD

Associate Professor of Ophthalmology
Director, Cataract, Cornea and Refractive Surgery
Cataract & Refractive Surgery Fellowship Director
Medical University of South Carolina
Storm Eye Institute
Charleston, SC

Vance Thompson, MD, FACS

Founder, Vance Thompson Vision
Professor of Ophthalmology
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD

George O. Waring IV, MD, FACS

Founder and Medical Director
Waring Vision Institute
Mount Pleasant, South Carolina

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allegro, Allergan, Avellino, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharmaceuticals, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharmaceuticals, Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculis, Orasis Pharmaceutical, Pogotec, RegenerEyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, TearLab, Veracity, Versant Ventures, Visionary Ventures, and Visus.

Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Orasis, Sun Pharmaceutical Industries, and Tarsus.

Karolinne M. Rocha, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Acufocus, Allergan, Alcon Vision, Baucsh + Lomb, Carl Zeiss Meditec, Dompé, Johnson & Johnson Vision, and LaserAce.

Vance Thompson, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Acufocus, Alcon Vision, Allergan, Allotex, Avellino, Avisi Technologies, Bausch + Lomb, BRIM Biotechology, BVI, Carl Zeiss Meditec, Centricity, Conjtac, CSO, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, Glaukos, Imprimis, iVeena, Johnson & Johnson Vision, Leica, LensAR, Melt Pharmaceuticals, Ocular Innovations, OneFocus, ORA, Oyster Point Pharma, Percept, ReFocus, RxSight, SightSciences, Stepwise Medical, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, Visus Therapeutics, and Vivior. Grant/Research Support: Acufocus, Alcon Vision, Allergan, Bausch + Lomb, BVI, Carl Zeiss Meditec, Centricity, Equinox, EyeGate Pharma, Glaukos, Johnson & Johnson Vision, Sight, Sight Sciences, Visus Therapeutics. Speakers Bureau: Acufocus, Alcon Vision, Glaukos, Johnson & Johnson Vision. Shareholder: Acufocus, Al Optics, Allotex, Avellino, Avisi Technologies, Centricity, Conjtac, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, iVeena, Melt Pharmaceuticals, Ocular Innovations, OneFocus, Oyster Point Pharma, Percept, RxSight, Sight Sciences, Singular Strategies, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, and Vivior.

George O. Waring IV, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Carl Zeiss Meditec, Johnson & Johnson, and Oculus.

The Evolve and The Fundingsland Group staff and planners and reviewers have no financial relationships with commercial interests.